Investigational Drug Information for Barusiban
✉ Email this page to a colleague
What is the drug development status for Barusiban?
Barusiban is an investigational drug.
There have been 4 clinical trials for Barusiban.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Premature Birth, Obstetric Labor, Premature, and Infertility. The leading clinical trial sponsors are Ferring Pharmaceuticals, Tel-Aviv Sourasky Medical Center, and [disabled in preview].
There are thirty-one US patents protecting this investigational drug and two hundred and sixty-eight international patents.
Summary for Barusiban
| US Patents | 31 |
| International Patents | 268 |
| US Patent Applications | 70 |
| WIPO Patent Applications | 53 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2016-03-01) |
| Vendors | 3 |
Recent Clinical Trials for Barusiban
| Title | Sponsor | Phase |
|---|---|---|
| Tocolytic Therapy for Preterm Labor in Multiple Gestation | Tel-Aviv Sourasky Medical Center | Phase 3 |
| Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
| Effect of Oxytocin Antagonist on Reduction of Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Barusiban
Top disease conditions for Barusiban
Top clinical trial sponsors for Barusiban
US Patents for Barusiban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Barusiban | See Plans and Pricing | Permeant delivery system and methods for use thereof | NITTO DENKO CORPORATION (Tokyo, JP) | See Plans and Pricing |
| Barusiban | See Plans and Pricing | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | Ferring B.V. (Hoofddorp, NL) | See Plans and Pricing |
| Barusiban | See Plans and Pricing | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | See Plans and Pricing |
| Barusiban | See Plans and Pricing | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (Newtown, PA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Barusiban
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Barusiban | Australia | AU2009231739 | 2028-03-31 | See Plans and Pricing |
| Barusiban | Canada | CA2720067 | 2028-03-31 | See Plans and Pricing |
| Barusiban | Canada | CA3084317 | 2028-03-31 | See Plans and Pricing |
| Barusiban | Canada | CA3138128 | 2028-03-31 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
